|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahn SH, Han MS, Yoon JH, Jeon SY, Kim CH,
Yoo HJ and Lee JC: Treatment of stage I non-small cell lung cancer
with CyberKnife, image-guided robotic stereotactic radiosurgery.
Oncol Rep. 21:693–696. 2009.PubMed/NCBI
|
|
3
|
Park S, Kim IR, Baek KK, Lee SJ, Chang WJ,
Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, et al: Prospective
analysis of quality of life in elderly patients treated with
adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol.
24:1630–1639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rice SJ, Miller B, Wagman M, Jamorabo DS,
Liu X and Belani CP: Clinical approaches to immunotherapy in
non-small cell lung cancer: Current and future perspectives. Curr
Mol Pharmacol. Jul 16–2015.(Epub ahead of print). PubMed/NCBI
|
|
5
|
Sangiolo D, Martinuzzi E, Todorovic M,
Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi
A, Geuna M, Casorzo L, et al: Alloreactivity and anti-tumor
activity segregate within two distinct subsets of cytokine-induced
killer (CIK) cells: Implications for their infusion across major
HLA barriers. Int Immunol. 20:841–848. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuçi S, Rettinger E, Voss B, Weber G,
Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S,
et al: Efficient lysis of rhabdomyosarcoma cells by
cytokine-induced killer cells: Implications for adoptive
immunotherapy after allogeneic stem cell transplantation.
Haematologica. 95:1579–1586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thanendrarajan S, Nowak M, Abken H and
Schmidt-Wolf IG: Combining cytokine-induced killer cells with
vaccination in cancer immunotherapy: More than one plus one? Leuk
Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmidt-Wolf IG, Finke S, Trojaneck B,
Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M,
Takeya M, et al: Phase I clinical study applying autologous
immunological effector cells transfected with the interleukin-2
gene in patients with metastatic renal cancer, colorectal cancer
and lymphoma. Br J Cancer. 81:1009–1016. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sangiolo D: Cytokine induced killer cells
as promising immunotherapy for solid tumors. J Cancer. 2:363–368.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu Y, Zhang H, Li Y, Bai J, Liu L, Liu Y,
Qu Y and Qu X: Efficacy of postoperative adjuvant transfusion of
cytokine-induced killer cells combined with chemotherapy in
patients with colorectal cancer. Cancer Immunol Immunother.
62:1629–1635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu
FM, He N, Pan CC, Xia JC, Wu PH and Zhao M: Cytokine-induced killer
cells in combination with transcatheter arterial chemoembolization
and radiofrequency ablation for hepatocellular carcinoma patients.
J Immunother. 36:287–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang J, Wu C and Lu B: Cytokine-induced
killer cells promote antitumor immunity. J Transl Med. 11:832013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Zhu L, Zhang Q, He X, Yin Y, Gu
Y, Guo R, Lu K, Liu L, Liu P and Shu Y: Effects of cytokine-induced
killer cell treatment in colorectal cancer patients: A
retrospective study. Biomed Pharmacother. 68:715–720. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang XP, Xu M, Gao HF, Zhao JF and Xu KC:
Intraperitoneal perfusion of cytokine-induced killer cells with
local hyperthermia for advanced hepatocellular carcinoma. World J
Gastroenterol. 19:2956–2962. 2013.PubMed/NCBI
|
|
17
|
Sobin LH, Gospodarowicz MK and Wittekind
CH: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Hoboken, NY: 2009.
|
|
18
|
Schmidt-Wolf GD, Negrin RS and
Schmidt-Wolf IG: Activated T cells and cytokine-induced
CD3+ CD56+ killer cells. Ann Hematol.
74:51–56. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y
and Shu Y: The effects of cytokine-induced killer cells for the
treatment of patients with solid tumors: A clinical retrospective
study. J Cancer Res Clin Oncol. 138:1057–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baas P, Belderbos JS and Van den Heuvel M:
Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin
Oncol. 23:140–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsu HS, Huang PI, Chang YL, Tzao C, Chen
YW, Shih HC, Hung SC, Chen YC, Tseng LM and Chiou SH: Cucurbitacin
I inhibits tumorigenic ability and enhances radiochemosensitivity
in nonsmall cell lung cancer-derived CD133-positive cells. Cancer.
117:2970–2985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun K, Wang L and Zhang Y: Dendritic cell
as therapeutic vaccines against tumors and its role in therapy for
hepatocellular carcinoma. Cell Mol Immunol. 3:197–203.
2006.PubMed/NCBI
|
|
23
|
Méndez R, Ruiz-Cabello F, Rodríguez T, Del
Campo A, Paschen A, Schadendorf D and Garrido F: Identification of
different tumor escape mechanisms in several metastases from a
melanoma patient undergoing immunotherapy. Cancer Immunol
Immunother. 56:88–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wongkajornsilp A, Somchitprasert T,
Butraporn R, Wamanuttajinda V, Kasetsinsombat K, Huabprasert S,
Maneechotesuwan K and Hongeng S: Human cytokine-induced killer
cells specifically infiltrated and retarded the growth of the
inoculated human cholangiocarcinoma cells in SCID mice. Cancer
Invest. 27:140–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu
HY and Wang CC: The impact of CD4+ CD25+ T
cells in the tumor microenvironment of hepatocellular carcinoma.
Surgery. 151:213–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW
and Zheng SS: Intratumoral regulatory T cells alone or in
combination with cytotoxic T cells predict prognosis of
hepatocellular carcinoma after resection. Med Oncol. 29:1817–1826.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Perdicchio M, Cornelissen LA,
Streng-Ouwehand I, Engels S, Verstege MI, Boon L, Geerts D, van
Kooyk Y and Unger WW: Tumor sialylation impedes T cell mediated
anti-tumor responses while promoting tumor associated-regulatory T
cells. Oncotarget. Jan 5–2016.(Epub ahead of print). PubMed/NCBI
|
|
28
|
Attallah AM, Tabll AA, El-Sadany M,
Ibrahim TA and El-Dosoky I: Dysregulation of blood lymphocyte
subsets and natural killer cells in schistosomal liver cirrhosis
and hepatocellular carcinoma. Clin Exp Med. 3:181–185. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Motz GT and Coukos G: Deciphering and
reversing tumor immune suppression immunity. Immunity. 39:61–73.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kiessling R, Wasserman K, Horiguchi S, et
al: Tumor-induced immune dysfunction. Cancer Immunol Immunother.
48:353–362. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rayman P, Uzzo RG, Kolenko V, Bloom T,
Cathcart MK, Molto L, Novick AC, Bukowski RM, Hamilton T and Finke
JH: Tumor-induced dysfunction in interleukin-2 production and
interleukin-2 receptor signaling: A mechanism of immune escape.
Cancer J Sci Am. 6(Suppl 1): S81–S87. 2000.PubMed/NCBI
|
|
32
|
Shepherd FA, Douillard JY and Blumenschein
GR Jr: Immunotherapy for non-small cell lung cancer: Novel
approaches to improve patient outcome. J Thorac Oncol. 6:1763–1773.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Subleski JJ, Wiltrout RH and Weiss JM:
Application of tissue-specific NK and NKT cell activity for tumor
immunotherapy. J Autoimmun. 33:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuss I, Hathaway B, Ferris RL, Gooding W
and Whiteside TL: Decreased absolute counts of T lymphocyte subsets
and their relation to disease in squamous cell carcinoma of the
head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmidt-Wolf IG, Lefterova P, Mehta BA,
Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS:
Phenotypic characterization and identification of effector cells
involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
36
|
Joshi PS, Liu JQ, Wang Y, Chang X,
Richards J, Assarsson E, Shi FD, Ljunggren HG and Bai XF:
Cytokine-induced killer T cells kill immature dendritic cells by
TCR-independent and perforin-dependent mechanisms. J Leukoc Biol.
80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Y, Lin WS, Zhu WF, Lin J, Zhou ZF,
Huang CZ, Chen G, Shi Y, Guo ZQ and Ye YB: Tumor MICA status
predicts the efficacy of immunotherapy with cytokine-induced killer
cells for patients with gastric cancer. Immunol Res. 64:251–259.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Blattman JN and Greenberg PD: Cancer
immunotherapy: A treatment for the masses. Science. 305:200–205.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu L, Zhang W, Qi X, Li H, Yu J, Wei S,
Hao X and Ren X: Randomized study of autologous cytokine-induced
killer cell immunotherapy in metastatic renal carcinoma. Clin
Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Verneris MR, Karimi M, Baker J, Jayaswal A
and Negrin RS: Role of NKG2D signaling in the cytotoxicity of
activated and expanded CD8+ T cells. Blood.
103:3065–3072. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schwaab T, Schwarzer A, Wolf B, Crocenzi
TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC,
Mellinger D, et al: Clinical and immunologic effects of intranodal
autologous tumor lysate-dendritic cell vaccine with Aldesleukin
(Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell
carcinoma patients. Clin Cancer Res. 15:4986–4992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li R, Wang C, Liu L, Du C, Cao S, Yu J,
Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer
cell immunotherapy in lung cancer: A phase II clinical study.
Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX,
Chen LJ, Zheng X, Sun J, Lu BF and Zhang XG: Increasing the
frequency of CIK cells adoptive immunotherapy may decrease risk of
death in gastric cancer patients. World J Gastroenterol.
16:6155–6162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G,
Guan J and Zhu W: Cord blood-derived cytokine-induced killer cells
biotherapy combined with second-line chemotherapy in the treatment
of advanced solid malignancies. Int Immunopharmacol. 11:449–456.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF,
Feng YY, Fan ZP, Xu DP and Wang FS: Autologous cytokine-induced
killer cell therapy in clinical trial phase I is safe in patients
with primary hepatocellular carcinoma. World J Gastroenterol.
10:1146–1151. 2004.PubMed/NCBI
|
|
46
|
Jiang J, Xu N, Wu C, Deng H, Lu M, Li M,
Xu B, Wu J, Wang R, Xu J and Nilsson-Ehle P: Treatment of advanced
gastric cancer by chemotherapy combined with autologous
cytokine-induced killer cells. Anticancer Res. 26:2237–2242.
2006.PubMed/NCBI
|
|
47
|
Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J
and Wu C: Efficacy of adjuvant immunotherapy with cytokine-induced
killer cells in patients with locally advanced gastric cancer.
Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jin CG, Chen XQ, Li J, Wu ZP, Liu X and
Wang XC: Moderating effects and maintenance of lung cancer cellular
immune functions by CIK cell therapy. Asian Pac J Cancer Prev.
14:3587–3592. 2013. View Article : Google Scholar : PubMed/NCBI
|
